FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutical industry, namely to methods of treating mydriasis. Method of treating mydriasis in a patient involves administering a dose of an alpha-adrenergic antagonist into the eye of a patient in need thereof, which ranges from 0.2 to 0.7 mg of phentolamine mesylate, for the treatment of mydriasis, where mydriasis occurs due to the fact that the patient has received an agent causing pupil dilation. Method of treating mydriasis in a patient, comprising administering into the eye of a patient in need thereof, a dose of an alpha-adrenergic antagonist, which is one or two eye drops of a solution containing phentolamine mesylate, for treating mydriasis is characterized by that mydriasis is caused by the fact that the patient has received an agent causing pupil dilation.
EFFECT: use of the group of inventions provides a long-term decrease in the diameter of the pupil in range of 1.8 to 2.1 mm for more than 3 hours, without causing undesirable side effects in the form of reddening of the eyes, burning, eyebrow pains or excessive pupil diameter reduction below 1.6 mm, as well as the group of inventions enables to improve accommodation and reduce intraocular pressure.
41 cl, 3 dwg, 34 tbl, 8 ex
